User talk:Oceanflynn/sandbox/Timeline Orphan Drugs

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Table in process

"These 25 biotechnology firms are ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares."

Of these the following are companies that produce orphan drugs for the US market: Abbott Laboratories, Acorda Therapeutics, Actelion Pharmaceuticals, Aegerion Pharmaceuticals, Alexion Pharmaceuticals, Allergan, Inc., Amgen, Ariad Pharmaceuticals, Astellas, AstraZeneca, Auxilium Pharmaceuticals, Inc. Bausch & Lomb Baxter International Bayer AG Biogen IDEC BioMarin Pharmaceutical, Inc. Boehringer Ingelheim Bristol-Myers Squibb Cangene Corporation Celgene Corporation CSL Behring Eisai Co., Ltd. Eli Lilly & Company EMD Serono Endo Health Solutions, Inc. (previously Endo Pharmaceuticals, Inc.) Exelixis, Inc. Gilead Sciences, Inc. GlaxoSmithKline Grifols, S.A. Hyperion Therapeutics, Inc. Incyte Corporation Ipsen, Inc. Jazz Pharmaceuticals plc Johnson & Johnson KV Pharmaceutical Company Merck & Company Novartis Novo Nordisk NPS Pharmaceuticals Octapharma USA, Inc. Onyx Pharmaceuticals, Inc. Otsuka Pharmaceutical Co., Inc. Pacira Pharmaceuticals, Inc. Pfizer, Inc. Rare Disease Therapeutics, Inc. Reckitt Benckiser Group plc Regeneron Pharmaceuticals, Inc. Roche Salix Pharmaceuticals, Inc. Sanofi Savient Pharmaceuticals, Inc. Seattle Genetics, Inc. Shire Plc Sigma-Tau Pharmaceuticals, Inc. Spectrum Pharmaceuticals Takeda Pharmaceutical Company Ltd. Talon Therapeutics, Inc. Teva Pharmaceuticals United Therapeutics Corporation Valeant Pharmaceuticals International, Inc. Vertex Pharmaceuticals, Inc.

caption

company	ranking 2013	2012	2013 Market Cap 2013	Market Cap 2012
1	Novo Nordisk	1	$85.335 billion (7/2: 535.0 million shares * price DKK 911.50)1,10	2012 Market Cap: $62.809 billion (7/2: 418.0 million shares * price DKK 859.00)1,10
2	Amgen	$78.695 billion (4/24: 749,976,556 shares * price $104.93)
3	Gilead Sciences	3	$78.373 billion (4/26: 1,525,355,825 shares * price $51.38)	$19.751 billion (4/27: 757,321,824 shares * price $26.08)
4	Celgene	7	$2013 Market Cap: $52.557 billion (4/23: 417,122,477 shares * price $126.00)	2012 Market Cap: $34.319 billion (4/25: 440,497,817 shares * price $77.91)
5	Biogen Idec	4	2013 Market Cap: $47.157 billion (4/18: 237,374,815 shares * price $198.66)	2012 Market Cap: $31.582 billion (5/1: 239,562,899 shares * price $131.83)

The following material from Genengnews is to be edited and entered into the table above:

"

1. 13. UCB

2013 Market Cap: $11.650 billion (3/31: 179.3 million shares * price €49.80 on 3/29)1,6

2012 Market Cap: $7.449 billion (3/31: 176.4 million shares * price €32.35 on 3/30)1,6

% Change: 56.4%

Position on 2012 List: #14

1. 12. Vertex Pharmaceuticals

2013 Market Cap: $17.495 billion (4/26: 221,400,864 shares * price $79.02)

2012 Market Cap: $8.151 billion (4/27: 211,061,148 shares * price $38.62)

% Change: 114.6%

Position on 2012 List: #11

1. 11. Shire

2013 Market Cap: $17.252 billion (4/29: 562,826,237 shares * price £20.17)

2012 Market Cap: $17.205 billion (4/27: 562,532,330 shares * price £20.13 on 4/26)

% Change: 0.3%

Position on 2012 List: Not on list

1. 10. Alexion

2013 Market Cap: $17.893 billion (4/23: 195,146,634 shares * price $91.69)

2012 Market Cap: $17.152 billion (4/20: 186,924,017 shares * price $91.76)

% Change: 4.3%

Position on 2012 List: #10

1. 9. Regeneron

2013 Market Cap: $20.269 billion (4/17: 95,122,401 shares * price $213.08)7

2012 Market Cap: $11.894 billion (4/11: 97,966,145 shares * price $121.41)7

% Change: 70.4%

Position on 2012 List: #12

1. 8. CSL

2013 Market Cap: $27.440 billion (6/30: A$30.042 billion) (dd)1,8

2012 Market Cap: $18.359 billion (6/30: A$20.099 billion) (dd)1,8

% Change: 49.5%

Position on 2012 List: #9

1. 7. Merck KGaA

2013 Market Cap: $33.364 billion (3/31: 217,388,939 shares * price €117.70 on 3/29)4

2012 Market Cap: $22.319 billion (3/31: 217,388,939 shares * price €78.72 on 3/30)4

% Change: 49.5%

Position on 2012 List: #8

1. 6. Teva Pharmaceutical Industries

2013 Market Cap: $33.768 billion (3/31: About 851 million shares * price $39.68 on 3/28)4,9

2012 Market Cap: $39.292 billion (3/31: About 872 million shares * price $45.06 on 3/30)4,9

% Change: -14.1%

Position on 2012 List: #5

1. 5. Biogen Idec

2013 Market Cap: $47.157 billion (4/18: 237,374,815 shares * price $198.66)

2012 Market Cap: $31.582 billion (5/1: 239,562,899 shares * price $131.83)

% Change: 49.3%

Position on 2012 List: #4

1. 4. Celgene

2013 Market Cap: $52.557 billion (4/23: 417,122,477 shares * price $126.00)

2012 Market Cap: $34.319 billion (4/25: 440,497,817 shares * price $77.91)

% Change: 53.1%

Position on 2012 List: #7

1. 3. Gilead Sciences

2013 Market Cap: $78.373 billion (4/26: 1,525,355,825 shares * price $51.38)

2012 Market Cap: $19.751 billion (4/27: 757,321,824 shares * price $26.08)

% Change: 296.8%

Position on 2012 List: #3

1. 2. Amgen

2013 Market Cap: $78.695 billion (4/24: 749,976,556 shares * price $104.93)

2012 Market Cap: $55.054 billion (4/26: 777,707,877 shares * price $70.79)

% Change: 42.9%

Position on 2012 List: #2

1. 1. Novo Nordisk

2013 Market Cap: $85.335 billion (7/2: 535.0 million shares * price DKK 911.50)1,10

2012 Market Cap: $62.809 billion (7/2: 418.0 million shares * price DKK 859.00)1,10

% Change: 35.9%

Position on 2012 List: #1

« Previous Page 1 2 Next Page »

Market cap is calculated by multiplying the number of outstanding shares by the share price. U.S. companies generally report their numbers of outstanding shares in their 10-Q quarterly or 10-K annual earnings filings with the Securities & Exchange Commission. Companies based outside the U.S. either disclose market cap directly, or their numbers of shares “in issue” or “in free issue” in half-year and full-year results disclosures. For all companies, closing share prices as of the dates of their outstanding-shares figures can be found through any of several free stock information websites. Figures of non-U.S. companies were converted to U.S. dollars from various currencies.

Notes: 1 Figures converted to U.S. dollars via www.xe.com on July 11, 2013 2 Market cap figures calculated as of March 31, the end of the company’s fiscal year, since outstanding shares figures were published in company’s annual report but not in Q1 results materials. 3 First-quarter figures for numbers of outstanding shares in Q1 2013 and Q1 2012 were rounded to the nearest tenth and furnished by the company in financial reports. 4 Prices are those at close of the trading day preceding March 31, since that day fell on a weekend during both 2013 and 2012. 5 First-quarter figures supplied by company for numbers of outstanding shares in Q1 2013 and Q1 2012 were rounded to the nearest tenth and included within press releases. 6 First-quarter figures supplied by company for numbers of weighted average shares outstanding in Q1 2013 and Q1 2012 were rounded to the nearest tenth and included within press releases. 7 2013 share count combines 95,908,088 shares of common stock and 2,058,057 shares of Class A stock; 2012 share count combines 93,032,889 shares of common stock and 2,089,512 shares of Class A stock. 8 Market capitalization figures included in the Top 40 with Market Capitalization list published July 2 by the Australian publication Biotech Daily. CSL furnishes figures on number of shares in its annual reports, the latest of which covers the 2011–12 fiscal year. 9 First-quarter figures supplied by company for numbers of outstanding shares in Q1 2013 and Q1 2012 were rounded to the nearest whole number and included within press releases.

10 Share price and number of shares data is available on the historic stock information section of company’s website, which rounds off total number of shares to the nearest whole number."

— www.genengnews.com